Ignite Creation Date:
2025-12-24 @ 10:09 PM
Ignite Modification Date:
2026-01-17 @ 8:07 AM
Study NCT ID:
NCT04425135
Status:
UNKNOWN
Last Update Posted:
2020-06-11
First Post:
2020-06-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
Sponsor:
The First Affiliated Hospital of Xiamen University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-01
Completion Date Type:
ESTIMATED
First Submit Date:
2020-06-08
First Submit QC Date:
None
Study First Post Date:
2020-06-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-06-08
Last Update Post Date:
2020-06-11
Last Update Post Date Type:
ACTUAL